Novo Nordisk Launches DTP Delivery Service for Wegovy
NovoCare will offer the GLP-1 injection to cash-paying patients for a discounted $499 per month.
Novo Nordisk, the manufacturer of Weggovy, is growing its offerings by creating NovoCare Pharmacy, a direct-to-patient (DTP) form of delivery that provides cash-paying patients with access to all dose strengths of Wegovy for $499 per month, at a lower cost.1
Intended for uninsured or eligible patients with commercial insurance who do not have obesity medication coverage, patients who need the 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg semaglutide injection will now be able to have those needs met.
NovoCare offers cash-paying patients who have been prescribed Wegovy with the opportunity to send shipments directly to their home. As of late February, the GLP-1 was taken off the shortage list after Novo began limiting new prescriptions due to high demand starting in 2022, although strain on the supply chain persisted through last year.2 The FDA has been on the record as stating that Novo is now able to meet the demand.
GLP-1s have traditionally treated type 2 diabetes, but have surged in popularity for battling weight loss; they have also recently been approved in other indications, such as cardiovascular disease prevention and sleep apnea.3 In fact, a KFF Health Tracking Poll supported their prominence, finding that about one in eight adults (12%) report taking a GLP-1 drug.3,4
Meanwhile, Ozempic made the Centers for Medicare & Medicaid Services’ 15 latest drugs to be covered under Part D for price negotiations, with adjusted prices becoming effective by 2027.5
"Novo Nordisk continues to advance solutions for patients that improve affordability and access to our medicines, whether they have insurance or not. Today, over 55 million people in the US have coverage specifically for weight management medicines, and 90% of Wegovy patients with coverage pay $0 to $25 a month for Wegovy," said Dave Moore, executive vice president, US operations and global business development and president of Novo Nordisk. "With NovoCare Pharmacy, patients and prescribers alike have another option that provides convenient access to all doses of real, FDA-approved Wegovy at a reduced cost in our high-quality pen."
References
1. Novo Nordisk introduces NovoCare Pharmacy, lowering cost of all doses of FDA-approved Wegovy (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients. PR Newswire. March 5, 2025. Accessed March 5, 2025. https://www.prnewswire.com/news-releases/novo-nordisk-introduces-novocare-pharmacy-lowering-cost-of-all-doses-of-fda-approved-wegovy-semaglutide-to-499-per-month-and-offering-easy-home-delivery-for-cash-paying-patients-302392874.html
2. Holland M. Ozempic and Wegovy Officially Taken Off Shortage List. Pharmaceutical Executive. February 27, 2025. Accessed March 5, 2025. https://www.pharmexec.com/view/ozempic-wegovy-taken-off-shortage-list
3. Saraceno N. Beyond the GLP-1 Headlines. Pharmaceutical Commerce. February 12, 2025. Accessed March 5, 2025. https://www.pharmaceuticalcommerce.com/view/beyond-the-glp-1-headlines
4. Montero A, Sparks G, Presiado M, Hamel L. KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs. KFF. May 10, 2024. Accessed March 5, 2025. https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/#:~:text=The%20latest%20KFF%20Health%20Tracking,6%25%20who%20say%20they%20are
5. Dowd C. Breaking Point: How 2025 Will Reshape Patient Support Services. Pharmaceutical Commerce. February 7, 2025. Accessed March 5, 2025. https://www.pharmaceuticalcommerce.com/view/breaking-point-how-2025-will-reshape-patient-support-services
